The following terms apply to this Agreement:
1. Recipient will acknowledge Provider in any publication that contains data or information about the Material by using the following statement: “This research was made possible through the Allen Cell Collection, available from Coriell Institute for Medical Research.”
In addition, the Recipient will cite the Material in the following manner:
In text: “<AICS cell line ID> (e.g., AICS-0025-044) developed at the Allen Institute for Cell Science (allencell.org/cell-catalog) and available through Coriell.” Primary publication to include in the citation for all cell lines EXCEPT for AICS-0037, -0048, -0052, -0060, -0063 and -0075: “Roberts, B. et al. (2017). Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization. Molecular Biology of the Cell, 28(21)” Primary publication to include in the citation for AICS-0037, -0048, -0052, -0060, -0063 and -0075 cell lines: “Roberts B, et al. (2019). Fluorescent Gene Tagging of Transcriptionally Silent Genes in hiPSCs. Stem Cell Reports 12(5)”
Further, Recipient Scientist will notify Provider of such publication by sending an email to publications@alleninstitute.org.
2. Recipient acknowledges that Coriell administers the Material by serving as the repository and distributor of the lines (“Administrator”). Recipient acknowledges that Provider also references and includes Administrator for any sections of the MTA that affect Administrator’s work on behalf of Provider in administration of this Agreement, except for sections referring to Provider Ownership or Intellectual Property rights.
3. Recipient acknowledges that the Original Material was made using third-party technologies and materials that are subject to the terms below. Recipient understands that some uses of the Material may require a license from the third party material provider and Provider accepts no liability in relation thereto.
4. If Recipient is a Provider-approved core facility and such Recipient receives the Material under a Core Facility Material Transfer Agreement, such Recipient shall incorporate their institution name into the name of the Material distributed to Recipient PIs and will acknowledge Provider and their expansion/scale-up of the Material in any publication that contains data or information about such expanded/scaled-up Material. Recipient shall use the following naming convention for labeling the expanded/scaled-up Material: <Recipient Name>-<AICS cell line ID> (e.g., <Recipient Name>-AICS-0012). In addition, Recipient shall use the following statement when acknowledging the Material in any publication: “This research uses <Recipient Name> core facility expanded cell lines made possible through the Allen Cell Collection, available from Coriell Institute for Medical Research.” In addition, Recipient Scientist will notify Provider of such publication by sending an email to publications@alleninstitute.org.
For cell lines AICS-0005, AICS-0010, AICS-0011, AICS-0012, AICS-0013, AICS-0014, AICS-0016, AICS-0017, AICS-0022-037, AICS-0023, AICS-0024, AICS-0025-001, AICS-0025-044, AICS-0030-022, AICS-0031-035, AICS-0032-019, AICS-0033-115, AICS-0034-062, AICS-0036-006, AICS-0036-0028, AICS-0037-172, AICS-0040-013, AICS-0040-035, AICS-0046-051, AICS-0048-039, AICS-0052-003, AICS-0053-016, AICS-0054-091, AICS-0057-050, AICS-0058-067, AICS-0059-036, AICS-0060-027, AICS-0061-036, AICS-0063-096, AICS-0068-009, AICS-0069-088, AICS-0074-026, AICS-0075-085, AICS-0078-079, AICS-0080-069, AICS-0082-001, AICS-0083-005, AICS-0083-124, AICS-0084-018, AICS-0086-147, AICS-0087-031, AICS-0088-083, AICS-0089-061, AICS-0090-391, AICS-0093-025, AICS-0094-024, AICS-0095-018, AICS-0096-074, AICS-0099-020, AICS-0114-032, AICS-0114-035, AICS-0126-041 and AICS-0126-068 AND
For Disease Collections AICS-0097, AICS-0104, AICS-0105, AICS-0106, AICS-0107, AICS-0109, AICS-0119, AICS-0113:
A. The Allen Cell Collection is a bank of human induced pluripotent stem cells that are currently derived from the WTC parental line released by the Conklin Laboratory at the J. David Gladstone Institute (available through Coriell as GM25256, where you can also find the de-identified patient information associated with the line).
Institutions using NIGMS Repository Sample(s) for use as reference materials or controls are responsible for complying with all laws and regulations applicable to intended use of the NIGMS Repository Samples(s), including any requirements for FDA approval.
B. Recipient acknowledges that the Material was made using the parental WTC line (“Gladstone Material”) from Bruce R. Conklin, M.D. at The J. David Gladstone Institutes (“Gladstone”), and Gladstone retains ownership rights to the Gladstone Material contained in the Material and contained or incorporated in any derivative materials or modifications made by RECIPIENT. Except to the extent prohibited by law, RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the Gladstone Material. Gladstone will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the Gladstone Material by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of Gladstone as determined by a court of competent jurisdiction. Gladstone makes no representations and provides no warranty that the use of the Material will not infringe any patent or other proprietary right. The transfer of the Material to RECIPIENT does not carry with it and does not grant any license, express or implied, under any patent. RECIPIENT SCIENTIST will acknowledge Gladstone as the source of the parental lines in all publications containing any data or information about such lines.
For cell lines AICS-0031-035, AICS-0032-019, AICS-0034-062, AICS-0054-091, AICS-0059-036, AICS-0078-079, AICS-0084-018, AICS-0086-147 and AICS-0089-061 and AICS-0090-391:
Recipient acknowledges that the Original Material encodes or comprises a Evrogen fluorescent protein. Obtaining this material does not convey to the recipient any rights to use the Evrogen fluorescent protein or nucleic acid encoding such protein. Limited research use rights may be obtained by purchasing of any vector encoding this particular fluorescent protein from Evrogen distributors, listed at http://www.evrogen.com/support/distributors.shtml
For obtaining additional (commercial) use rights please contact Evrogen directly at: license@evrogen.com
For cell line AICS-0086-147:
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT.
Researchers may use this product for research use only, no commercial use is allowed. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the HaloTag® gene. Researchers may however clone heterologous DNA sequences at either or both ends of said HaloTag® gene so as to create fused gene sequences provided that the coding sequence of the resulting HaloTag® gene has no more than four (4) deoxynucleotides missing at the affected terminus when compared to the intact HaloTag® gene sequence. In addition, researchers must do one of the following in conjunction with use of the product: (1) use Promega HaloTag® ligands, which can be modified or linked to Promega or customer-supplied moieties, or (2) contact Promega to obtain a license if Promega HaloTag® ligands are not to be used. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT.
